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Abstract Botulinum toxin type A is a 150 kD protein produced byClostridium botulinum, which exists in a complex
with up to six additional proteins. The ability of botulinum toxin to inhibit acetylcholine release at the
neuromuscular junction has been exploited for use in medical conditions characterized by muscle hyper-
activity. As such, botulinum toxin is widely recommended by international treatment guidelines for move-
ment disorders and it has a plethora of other clinical and cosmetic indications. The chronic nature of these
conditions requires repeated injections of botulinum toxin, usually every few months. Multiple injections
can lead to secondary treatment failure in some patients that may be associated with the production of
neutralizing antibodies directed specifically against the neurotoxin. However, the presence of such anti-
bodies does not always render patients non-responsive. The reported prevalence of immunoresistance varies
greatly, depending on factors such as study design and treated indication. This review presents what is
currently known about the immunogenicity of botulinum toxin and how this impacts upon patient non-
response to treatment. The complexing proteins may act as adjuvants and stimulate the immune response.
Their role and that of neutralizing and non-neutralizing antibodies in the response to botulinum toxin is
discussed, together with an assessment of current neutralizing antibody measurement techniques. Botu-
linum toxin preparations with different compositions and excipients have been developed. The major
commercially available preparations of botulinum toxin are Botox (onabotulinumtoxinA; Allergan, Inc.,
Ireland), Dysport (abobotulinumtoxinA; Ipsen Ltd, UK), and Xeomin (incobotulinumtoxinA; botu-
linum toxin type A [150 kD], free from complexing proteins; NT 201; Merz Pharmaceuticals GmbH,
Germany). The new preparations of botulinum toxin aim to minimize the risk of immunoresistance in
patients being treated for chronic clinical conditions.
1. Introduction
The anaerobic, spore-forming, rod-shaped bacterium, Clos-
tridium botulinum, produces the botulinum toxin, which causes
botulism after ingestion. The botulinum toxin complex con-
tains a 150 kD neurotoxin together with a complex of up to six
additional proteins. The neurotoxin is cleaved by clostridial
proteases into a heavy chain (~100 kD), which binds to ganglio-
sides and a protein receptor on pre-synaptic nerve endings, and
a light chain (~50 kD), which blocks the release of the neuro-
transmitter acetylcholine, causing dose-dependent weakening
of the target muscle.
There are seven immunologically distinct serotypes of bot-
ulinum toxin (A to G), of which types A and B are used clin-
ically. The latest commercially available botulinum neurotoxin
type A is Xeomin (incobotulinumtoxinA; botulinum toxin
type A [150 kD], free from complexing proteins; NT 201; Merz
Pharmaceuticals GmbH, Germany). Botulinum toxin type A is
also marketed as Botox (onabotulinumtoxinA; Allergan, Inc.,
Ireland), Dysport (abobotulinumtoxinA; Ipsen Ltd, UK) and
there are also Chinese formulations not described here. There
are differences between the botulinum toxin drug substances,
such as the bacterial strains from which they are produced, the
manufacturing processes, and the type or quantity of excipients
contained in each formulation.Currently, the only botulinum toxin
type B product available is Myobloc (rimabotulinumtoxinB;
Solstice Neurosciences Inc., USA; also called Neurobloc; Eisai
Europe Ltd, UK in some countries).
Botulinum toxin was first used clinically in the late 1970s in
ophthalmology to treat strabismus,[1] and over the last 20 years
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has gained widespread use in conditions requiring inhibition of
excessivemuscle spasm. The broad range ofmedical indications
for botulinum toxin include treatment of movement disorders
(e.g. spasticity, cervical dystonia), urological disorders (e.g.
overactive bladder), dermatological conditions (e.g. axillary hy-
perhidrosis), as well as cosmetic applications. As the indicated
clinical conditions are chronic in nature and the botulinum
toxin effects typically last no more than several months, patients
have to be injected repeatedly to maintain symptom control.
The European Federation of Neurological Societies (EFNS)
dystonia guidelines recommend botulinum toxin typeA as first-
line treatment for primary cranial (excluding oromandibular)
or cervical dystonia, and state that it is also effective for writing
dystonia.[2] Botulinum toxin type B can be used if there is re-
sistance to type A.[3] An evidence-based systematic review by
the American Academy of Neurology (AAN) states that bot-
ulinum toxin injections should be offered as a treatment option
for cervical dystonia and may be offered for blepharospasm,
focal upper extremity dystonia, adductor laryngeal dystonia,
and upper extremity tremor.[4] A lower level of evidence was
detected for hemifacial spasm, focal lower limb dystonia, and
motor tics. Another AAN evidence-based systematic review
recommends botulinum toxin for the treatment of spasticity in
adults and children with the strongest evidence (level A).[5]
Botulinum toxin is regarded as foreign by the host and there-
fore has the potential to induce an immune response, particularly
with repeated administration, which can lead to secondary treat-
ment failure. This review will discuss the response to botulinum
toxin over time, including current understanding of the immu-
nogenicity of botulinum toxin and its clinical implications.
2. Patient Non-Responsiveness to Treatment
Many patients respond well to treatment with botulinum
toxin but, for a variety of reasons, some patients do not.[6] Non-
response can be defined as a lack of patient (subjective) or
physician (objective) satisfaction with the therapeutic outcome
of a drug. It may be transient, in which one application of the
treatment is not efficacious but subsequent applications are, or
permanent, such that neither the first nor subsequent applica-
tions produce the desired clinical effect. Similarly, there may be
only a partial lack of response (some therapeutic aspects are not
achieved) or a complete lack of response (no therapeutic or side
effects can be detected).
Primary non-response refers to a lack of response to treat-
ment from the first application. It may occur in patients with
pseudo-dystonia, or those with a clinical subtype that has re-
duced sensitivity to botulinum toxin, such as anterocollis in
cervical dystonia, and sensory blepharospasm.[6] Misdiagnosis
is another important cause of primary non-response. For exam-
ple,myasthenia gravis is not treated by botulinum toxin, but the
first noticeable symptom is often weakness of the eyemuscles,[7]
and so it may be mistaken for blepharospasm (for which bot-
ulinum toxin treatment is indicated).[6] Inadequate dosing,
handling errors during drug storage or preparation, or prob-
lems with drug administration (e.g. an inaccessible muscle or
injection into the wrong muscle) can also cause either a primary
or secondary non-response.[6]
Secondary non-response occurs during the course of therapy
when a previously effective treatment no longer produces clini-
cal benefit. This is often subjectively described and influenced
by a patient’s expectation. Sometimes there may be a placebo
effect of the first series of treatment, or the patients return for a
re-injection before they have returned to baseline. Other patient
factors also have an effect, as some disorders worsen over time
and can be exacerbated by stress. In addition, the despondency
caused by a chronic debilitating condition can result in symp-
tom deterioration such that a previously efficacious dose in-
duces a subclinical response.[6]
An important reason for secondary treatment failure of any
therapeutic protein is its neutralization by antibodies; even
proteins with an identical sequence to the human protein can be
immunogenic.[8] The clinical effectmaywane gradually, eventually
leading to complete treatment failure. In one study of 27 patients
with complete treatment failure due to neutralizing antibodies, the
majority (81%) of patients had previously experienced partial
antibody-induced treatment failure.[9] Most patients in this
study developed complete treatment failure within 40 months
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Fig. 1. Histogramshowing latencies between the initiation of botulinum toxin
therapy and the occurrence of complete antibody-induced therapy failure in a
study of 27 patients.[9]
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3. Neutralizing and Non-neutralizing Antibodies
Native botulinum toxin is a complex of the 150 kD neuro-
toxin and other non-toxic clostridial proteins, including he-
magglutinins. All of these foreign proteins are antigens and
have the potential to induce an immune response, but only the
neurotoxin component has a therapeutic effect. Antibodies that
block its pharmacological effects are termed neutralizing or block-
ing antibodies. The non-toxic clostridial proteins, collectively
referred to as complexing proteins or neurotoxin-associated
proteins (NAPs), protect the neurotoxin against degradation in
the acidic conditions of the host gastrointestinal tract (partic-
ularly in the stomach).[10] Under physiological pH conditions,
the complexing proteins dissociate almost completely from the
neurotoxin following constitution with saline and even before
injection into the target tissue.[11] Therefore, complexing pro-
teins are not expected to improve clinical outcome in therapeutic
use of botulinum toxin, and specific antibodies generated against
the complexing proteins are termed non-neutralizing.However,
complexing proteins increase the bacterial protein load and can
potentially increase the immunogenic risk of neutralizing an-
tibody formation.
In amouse study, the production of antibodies was increased
with botulinum toxin type B in a large toxoid complex com-
pared with the neurotoxoid alone.[12] The presence of the com-
plexing proteins was associated with adjuvant activity via the
interleukin-6 cytokine pathway. Another preclinical study showed
that the botulinum neurotoxoid type A with complexing pro-
teins triggered a stronger immune response than the purified
150 kD neurotoxoid alone.[13] This study reported that hemag-
glutinin Hn-33 exhibited stronger immunogenicity than the
purified neurotoxoid typeA.AsHn-33 is the largest component
of the complexing proteins, this result indicated that Hn-33 is
themost immunogenic component of the botulinum toxin typeA
complex. These studies utilized formaldehyde-inactivated tox-
oids rather than native proteins, which will have affected their
immunogenicity,[13,14] and it has been noted that some of the
methods used in the mouse study[12] may differ from the use
of botulinum toxin in therapeutic applications.[14] Although
further investigations are needed, these studies revealed that
the toxoid complex is more immunogenic than the purified
neurotoxoid. The immunogenicity of toxoid components is of
relevance since toxoid components (i.e. inactive neurotoxin –
albeit not through formaldehyde inactivation) are contained in
some commercial botulinum toxin products.[15] It has therefore
been proposed that reducing the foreign protein load of botu-
linum toxin by removal of the complexing proteins would help
to reduce the formation of neutralizing antibodies, without
affecting therapeutic efficacy. The use of purified neurotoxin
preparations could potentially reduce the rate of secondary
treatment failure.
The role of complexing proteins has been further inves-
tigated in a recent in vitro study of the binding properties of the
type A neurotoxin complex. The neurotoxin alone did not in-
teract with non-neuronal cell types, but the complexing pro-
teins (both alone and in complex with the neurotoxin) were
shown to bind to neuroblasts, lymphoblasts, skeletal muscle
cells, and skin fibroblasts.[16] These findings raise the possibility
that other, as yet unconfirmed, detrimental effects of complex-
ing proteins may occur in host tissues, which may not directly
influence the neurotoxin mechanism of action, but instead have
an indirect effect similar to the adjuvant stimulation of neutralizing
antibodies that block the clinical effects of the neurotoxin.
4. Attempts to Overcome Antibody-Induced
Treatment Failure
Attempts to overcome the effects of antibody-induced treat-
ment failure have had limited success. Massively increased
botulinum toxin doses cannot overcome complete antibody-
induced treatment failure, although it has been suggested that
perhaps this may be effective in partial treatment failure.[6]
However, this strategy is simply expected to exacerbate the
problem because the antibody response will increase when the
antigen dose is increased.[17]
The use of different botulinum toxin serotypes has also been
investigated; an initial study of botulinum toxin type B dem-
onstrated efficacy for the treatment of patients with type
A-resistant cervical dystonia.[18] However, in a later study,
botulinum toxin type B appeared to be only temporarily ef-
fective in most patients with type A resistance.[19] Patients may
respond to the alternate serotype but eventually experience
treatment failure due to the development of antibodies against
the second botulinum toxin. These patients may also be primed
to develop antibodies to the second serotype due to cross-
reactivity between the first and second toxins.[17] Therefore,
once a patient has produced neutralizing antibodies against one
serotype, switching to another is unlikely to produce a clinical
response because immunoresistance to the second serotype will
develop swiftly. Prior resistance to botulinum toxin type A has
been shown to be an important risk factor for the development
of anti-botulinum toxin type B antibodies.[20] Clinical evidence
suggests that botulinum toxin type B has low specific biological
activity and ismore immunogenic than botulinum toxin type A,
inducing secondary treatment failure after only a few injec-
tions,[20-22] although it should be noted that botulinum toxin
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type B is applied in a markedly higher dose (higher protein
load), which might be the reason for antibody production. The
preferred approach is to prevent the formation of neutralizing
antibodies in the first place.
5. Clinical Relevance of Antibodies
Neutralizing antibodies against the botulinum toxin may
lead to issues with efficacy, and ultimately treatment failure as
described above. Antigenicity is generally proportional to pro-
tein load, and a higher protein load per dose of botulinum toxin
has been identified as a risk factor for increased antibody
titer.[20,23-25] This has been illustrated by the 5-fold reduction in
protein load within the current onabotulinumtoxinA type com-
pared with the original preparation, which has corresponded
with a reduced incidence of neutralizing antibodies. Previous
studies reported that up to 17% of patients with cervical dys-
tonia treated with the original onabotulinumtoxinA prepara-
tion had neutralizing antibodies.[26,27] A database review of
patients with cervical dystonia from a single clinic reported that
neutralizing antibodies were detected in four (9.5%) out of
42 patients who received the original preparation (100U/25 ng
protein) versus none of 119 patients using the newer product
(100U/5 ng protein).[26] The authors concluded that this was
related to the lower protein load.[26]
IncobotulinumtoxinA is a botulinum neurotoxin product
that does not contain complexing proteins.[15,28-30] Initial ex-
periments indicate that the minimized total protein load results
in reduced immunogenic potential. Repeated intramuscular ad-
ministration of high-dose incobotulinumtoxinA (up to 16U/kg
bodyweight) to cynomolgus monkeys did not induce detect-
able levels of neutralizing antibodies even when administered
every 4 weeks for 4 months.[31] Similarly, in a rabbit model, the
development of neutralizing antibodies was observed with
abobotulinumtoxinA and onabotulinumtoxinA, but not with
incobotulinumtoxinA, even when administered at doses up to
five times greater than those recommended for clinical use.[32]
IncobotulinumtoxinAhas a lowprotein content, but a high specific
activity, and retains clinical efficacyand safetyprofiles equivalent to
conventional botulinum toxin type A formulations.[15,33] In con-
trast to conventional formulations, incobotulinumtoxinA contains
the pure 150 kD neurotoxin, free from complexing protein, and
thus has a low foreign protein content. The amount of foreign
protein content administered is considered as one of the factors
for secondary treatment failure.[34]
Recent peer-reviewed publications and presentations of cur-
rent botulinum toxin formulations containing complexing pro-
teins in long-term studies in cervical dystonia or spasticity have
reported neutralizing antibodies in up to 6.6% of patients.[35-40]
It should be noted that no controlled, long-term studies have
compared the immunogenicity of different botulinum toxin
products. Variability in the reported prevalence of neutralizing
antibodies could be related to factors such as indication, ad-
ministered dosages, assay methods, timing of serum sample
testing, whether or not patients had previously received botu-
linum toxin therapy, and duration of treatment.[36]
Studies of botulinum toxin type A containing complexing
proteins suggest that, in addition to an increased protein load, a
higher dosing frequency and greater number of injections (and
the use of booster injections 2–3 weeks after original injections)
may also increase the risk of neutralizing antibodies.[6,41,42]
Higher rates of neutralizing antibodies have also been reported
in pediatric patients (approximately 30% of patients) who were
prescribed current botulinum toxin type A formulations.[42,43]
This may be an age-related feature of the immune response[44]
or a dose-related effect, as suggested by the authors of one of these
pediatric studies, due to the higher dose per kilogram body
weight in this age group.[42] A study of botulinum toxin type A
in patients with urologic disorders (hyperactive detrusor or
sphincter dysfunction) has reported the presence of antibodies
against botulinum toxin in a higher proportion of patients
(4/25 patients; 16%) than observed in cervical dystonia.[45] The
authors speculate that this may be because the urinary bladder
(with its urothelium) is an immunoreactive organ that responds,
for example, to urinary tract infections, which may also sensi-
tize bladders to other antigens.
A waning clinical response to botulinum toxin over several
injection sessions is generally the trigger to investigate whether
neutralizing antibodies are being produced. However, immune
responses can differ between patients, and the reduced clinical
response could also be caused by either acute or delayed re-
actions such as hypersensitivity or the formation of immune
complexes.[44] Although it is important to detect the presence of
neutralizing antibodies, their clinical impact should also be
determined as they do not always lead to treatment failure, and
thus antibody titers may occur at a subclinical level.[20,40,46,47]
Determining the true clinical impact of neutralizing anti-
bodies in patients treated with botulinum toxin is complicated
by the limitations of antibody measurement techniques and
inter-clinic variability regarding the definition of secondary
non-responsiveness.[22]
6. Neutralizing Antibody Measurement Techniques
If neutralizing antibody production is suspected because the
clinical effects of botulinum toxin decline and other causes of
e4 Benecke
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treatment failure have been excluded, biochemical and/or
functional tests can be employed to detect antibodies against
botulinum toxin (table I).
Enzyme-linked immunosorbent assay (ELISA) and fluo-
rescence immunoassay (FIA) tests are useful first screening
tools, and the immunoprecipitation assay (IPA) is also used.
However, these laboratory screening tests are not able to dis-
tinguish between neutralizing and non-neutralizing antibodies.
The hemidiaphragm assay (HDA) and the mouse protection
assay (MPA) are so far the only available laboratory functional
assays for the detection of neutralizing antibodies, and provide
good sensitivity. However, a key disadvantage of the MPA is
that in vivo animal testing is needed. The HDA test has higher
sensitivity than MPA and this may result in detection of sub-
clinical antibody titers that do not result in treatment failure.
Therefore, in clinical practice, a clinical test should also be in-
cluded to evaluate cases of antibody-induced treatment failure.
Functional assessments performed directly on the individual
patient in the clinic yield results within days or weeks. They
include the extensor digitorum brevis (EDB) test, the unilateral
brow injection (UBI) test, the sternocleidomastoid (SCM) test,
and the sudomotor sweat test.[6,35,55,57]
7. Botulinum Toxin Products
Botulinum toxin products vary considerably in pharmaceutical
composition (table II). These different physicochemical prop-
erties, coupled with the lack of standardization for measuring
their potency (i.e. biological activity; expressed in U/ng protein,
in which 1U is the lethal dose in 50% of mice tested [LD50]),[15]
means that the dosage cannot simply be interchanged between
brands.[5] Reports of the effective botulinum toxin type A clini-
cal conversion ratios (i.e. U of Product X producing a similar
clinical effect to U of Product Y) vary considerably in the lit-
erature, ranging up to 11 : 1 U for abobotulinumtoxinA :
onabotulinumtoxinA,[65,66] although it is generally agreed that
there is a 1 : 1U dose conversion rate between onabotuli-
numtoxinA and incobotulinumtoxinA.[32,67-69]
Recently, Frevert[15] sought to compare the neurotoxin con-
tent of each agent with a new and more sensitive ELISA, and
found that 100U of onabotulinumtoxinA, abobotulinumtox-
inA, and incobotulinumtoxinA contained 0.73 ng, 0.65 ng, and
0.44 ng of neurotoxin, respectively (table II; figure 2). Calcu-
lations based on these data showed that the highest specific
neurotoxinactivitywas found in incobotulinumtoxinA (227U/ng),
followed by abobotulinumtoxinA (154U/ng) and onabotuli-
numtoxinA (137U/ng). As incobotulinumtoxinA and onabo-
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these findings suggest that 0.44 ng of incobotulinumtoxinA
neurotoxin has the same biological activity as 0.73ng of onabo-
tulinumtoxinA neurotoxin, and the authors therefore concluded
that some of the 150 kD neurotoxin in onabotulinumtoxinA is
likely to be inactive (possibly denatured), adding further pro-
tein load in addition to the complexing proteins to the injected
dose.[15] OnabotulinumtoxinA is unique among the botulinum
toxin typeA formulations in that it is vacuumdried by a process
involving sodium chloride, which may have a detrimental effect
on neurotoxin activity[28] and may be responsible for its higher
toxoid (inactive neurotoxin) content.[15] This additional amount of
inactive/denatured protein could increase the production of
neutralizing antibodies against the onabotulinumtoxinA neu-
rotoxin, leading to a greater risk of therapeutic failure. In con-
trast, incobotulinumtoxinA has a low neurotoxin (and overall
protein) content but retains a high biological potency, so a
comparatively small amount of protein confers clinical benefit
while potentially carrying a lower risk of stimulating the pa-
tient’s immune system.[15] There has been discussion that the
units of each botulinum product are not interchangeable due to
differences in in-house LD50 protocols, which result in differ-
ences in the potencies reported, and hence bias in the specific
activities that were calculated.[70,71] However, the potency assay
demonstrates the same number of units for onabotulinumtox-
inA and incobotulinumtoxinA, as reported in the product
label.[34,71] Moreover, several clinical studies have reported
clear equipotency for these agents.[67,68,72]
8. Conclusions
Development of neutralizing antibodies against botulinum
neurotoxin is often the reason for secondary treatment failure.
The presence of complexing proteins within botulinum neuro-
toxin agents increases the protein load and may exacerbate an
immune response. Further studies investigating the long-term
immunological effects of different botulinum toxin products
are required, and it may be helpful to develop a consensus ap-
proach to schedules and techniques for antibody testing, as well
as a more precise definition of what constitutes treatment fail-
ure. Better understanding of the possible immunological in-
fluence of the manufacturing techniques and constituents used
in different botulinum toxin formulations is also needed. In the
interim, physicians must use their clinical experience to decide
how and when to treat their patients in order to minimize the
risk of immunoresistance.
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